HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Lowers Price Target to $27

Benzinga Newsdesk www.benzinga.com Negative 57.2%

Neg 57.2% Neu 0% Pos 0%

HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $47 to $27.